ShangPharma Corporation (NYSE:SHP) (?ShangPharma? or the ?Company?), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that Kevin Chen, Chief Operating Officer and Chief Financial Officer of ShangPharma, will be presenting at two investor conferences in Hong Kong on December 6 and 7, 2010:

  • Citi
    Hong Kong/China Mini Conference 2010 (Theme: Healthcare)
    December 6 – 7, 2010
  • Bank of America Merrill Lynch
    New China IPOs Corporate Day
    December 7, 2010

Presentation materials can be found under the ?Webcast and Presentation' section of the Company's investor relations website: http://ir.shangpharma.com.

About ShangPharma Corp.

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

ShangPharma Corporation
Lan Xie
VP of Finance and Operations
IR@shangpharma.com
or
Christensen
Kimberly Minarovich, +1-917-533-3268 (New York)
kminarovich@ChristensenIR.com
Tip Fleming, +852-9212-0684 (Hong Kong)
tfleming@ChristensenIR.com